Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
Lexicon Pharmaceuticals (NASDAQ:LXRX) announced upcoming presentations of clinical data for pilavapadin, their investigational AAK1-inhibitor for treating diabetic peripheral neuropathic pain (DPNP), at three major medical meetings.
The presentations will take place at NeuroDiab (September 11-14, Romania), the European Association for the Study of Diabetes (EASD) (September 16-19, Austria), and Arrowhead's 19th Annual Pain Therapeutics Summit (October 13-14, California). Key data from the Phase 2b PROGRESS trial and pilavapadin's potential as a non-opioid treatment option will be discussed by prominent medical experts.
Lexicon Pharmaceuticals (NASDAQ:LXRX) ha annunciato che presenterà dati clinici sul pilavapadin, il loro inibitore sperimentale di AAK1 per il trattamento del dolore neuropatico periferico diabetico (DPNP), in tre importanti congressi medici.
Le presentazioni si terranno a NeuroDiab (11-14 settembre, Romania), all'European Association for the Study of Diabetes (EASD) (16-19 settembre, Austria) e al 19th Annual Pain Therapeutics Summit di Arrowhead (13-14 ottobre, California). Esperti clinici di rilievo discuteranno i dati principali dello studio di Fase 2b PROGRESS e del potenziale del pilavapadin come opzione terapeutica non oppioide.
Lexicon Pharmaceuticals (NASDAQ:LXRX) anunció próximas presentaciones de datos clínicos sobre pilavapadin, su inhibidor experimental de AAK1 para el tratamiento del dolor neuropático periférico diabético (DPNP), en tres importantes congresos médicos.
Las presentaciones tendrán lugar en NeuroDiab (11-14 de septiembre, Rumanía), en la European Association for the Study of Diabetes (EASD) (16-19 de septiembre, Austria) y en el 19th Annual Pain Therapeutics Summit de Arrowhead (13-14 de octubre, California). Reconocidos expertos médicos expondrán los datos clave del ensayo de Fase 2b PROGRESS y el potencial de pilavapadin como alternativa no opioide.
Lexicon Pharmaceuticals (NASDAQ:LXRX)는 당뇨성 말초 신경병증성 통증(DPNP) 치료를 위한 실험적 AAK1 억제제인 pilavapadin의 임상 데이터를 세 곳의 주요 학회에서 발표할 예정이라고 밝혔다.
발표는 NeuroDiab(9월 11-14일, 루마니아), European Association for the Study of Diabetes (EASD)(9월 16-19일, 오스트리아), 및 Arrowhead의 제19회 연례 통증 치료 서밋(10월 13-14일, 캘리포니아)에서 진행된다. 주요 Fase 2b PROGRESS 시험 데이터와 pilavapadin이 비오피오이드 대안으로서 지닐 수 있는 잠재력에 대해 저명한 의학 전문가들이 논의할 예정이다.
Lexicon Pharmaceuticals (NASDAQ:LXRX) a annoncé la présentation prochaine de données cliniques sur le pilavapadin, son inhibiteur expérimental d'AAK1 destiné au traitement de la douleur neuropathique périphérique diabétique (DPNP), lors de trois grandes réunions médicales.
Les présentations auront lieu à NeuroDiab (11-14 septembre, Roumanie), à la European Association for the Study of Diabetes (EASD) (16-19 septembre, Autriche) et au 19th Annual Pain Therapeutics Summit d'Arrowhead (13-14 octobre, Californie). Des experts médicaux de renom discuteront des données clés de l'essai de phase 2b PROGRESS et du potentiel du pilavapadin en tant qu'option thérapeutique non opioïde.
Lexicon Pharmaceuticals (NASDAQ:LXRX) kündigte an, klinische Daten zu pilavapadin – ihrem experimentellen AAK1-Inhibitor zur Behandlung von diabetischer peripherer Neuropathie-Schmerz (DPNP) – auf drei großen medizinischen Tagungen vorzustellen.
Die Präsentationen finden auf der NeuroDiab (11.–14. September, Rumänien), der European Association for the Study of Diabetes (EASD) (16.–19. September, Österreich) und dem 19th Annual Pain Therapeutics Summit von Arrowhead (13.–14. Oktober, Kalifornien) statt. Führende medizinische Experten werden wichtige Ergebnisse der Phase‑2b‑Studie PROGRESS sowie das Potenzial von pilavapadin als nicht‑opioide Behandlungsoption erörtern.
- None.
- None.
Insights
Lexicon's pilavapadin data presentations at multiple conferences signal advancing development of their non-opioid pain treatment for diabetic neuropathy.
Lexicon Pharmaceuticals' upcoming presentations on pilavapadin across three major medical conferences represents meaningful progress in their clinical development pipeline. The drug, an AAK1-inhibitor with non-opioid properties, targets diabetic peripheral neuropathic pain (DPNP), a significant unmet medical need affecting millions of diabetic patients worldwide.
The coordinated presentation strategy across NeuroDiab, EASD, and Arrowhead's Pain Summit indicates strong confidence in their Phase 2b data. Having Dr. Rodica Pop-Busui, a distinguished diabetes researcher, present at two of these conferences adds scientific credibility to the program. The Phase 2b PROGRESS trial results appear robust enough to warrant multiple scientific forums, suggesting positive efficacy signals.
This strategic multi-conference approach is particularly noteworthy as it allows Lexicon to reach diverse but complementary audiences: diabetes specialists at EASD and NeuroDiab, and pain management experts at Arrowhead's Pain Summit. This comprehensive outreach suggests Lexicon is building awareness and support among key opinion leaders across multiple specialties that would influence both prescription patterns and potential partnership interest.
For investors, these presentations represent a de-risking event as the company progresses toward potential Phase 3 trials. The non-opioid mechanism of action positions pilavapadin advantageously in the current clinical landscape where alternatives to opioids are highly sought after for chronic pain conditions.
Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP)
Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annual Pain Summit
THE WOODLANDS, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic peripheral neuropathic pain (DPNP) at three upcoming medical meetings.
Details for the presentations are as follows:
NeuroDiab, September 11-14 in Bucharest, Romania:
| - | Lecture 3: New Promise for Painful Diabetic Neuropathy: Results from recently finished clinical trials of Pilavapadin, an oral, non-opioid, AAK1 inhibitor for diabetic peripheral neuropathic pain |
| - | Date: Saturday, September 13, 2025 |
| - | Time: 11:15 a.m. CEST |
| - | Presenter: Rodica Pop-Busui M.D., Ph.D., Jordan Schnitzer Chair in Diabetes, Professor of Medicine and Division Head, Endocrinology, Diabetes and Clinical Nutrition Director, Harold Schnitzer Diabetes Center, Oregon Health & Science University |
European Association for the Study of Diabetes (EASD), September 16-19 in Vienna, Austria:
| - | Oral Presentation: Pilavapadin, an oral, non-opioid, AAK1 inhibitor for diabetic peripheral neuropathic pain (DPNP): results from a Phase 2b, dose-ranging, randomized, placebo-controlled, multicenter study |
| - | Date: Wednesday, September 17, 2025 |
| - | Time: 10:30 a.m. CEST |
| - | Location: Sofia Hall |
| - | Presenter: Rodica Pop-Busui M.D., Ph.D., Jordan Schnitzer Chair in Diabetes, Professor of Medicine and Division Head, Endocrinology, Diabetes and Clinical Nutrition Director, Harold Schnitzer Diabetes Center, Oregon Health & Science University |
Arrowhead’s 19th Annual Pain Therapeutics Summit, October 13-14 in San Diego, CA:
| - | Poster: Pilavapadin in Neuropathic Pain: Results from the Phase 2b PROGRESS Trial in Patients with Diabetic Peripheral Neuropathic Pain |
| - | Date: Monday, October 13, 2025 |
| - | Time: 3:25 p.m. PT |
| - | Presenter: Suma Gopinathan Ph.D., VP Clinical Development, Lexicon Pharmaceuticals |
About Pilavapadin
Discovered using Lexicon’s unique approach to gene science, pilavapadin (LX9211) is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1, a novel target for neuropathic pain which inhibits reuptake and recycling of neurotransmitters involved in pain signaling without affecting opiate pathways. Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain. Preclinical studies of pilavapadin demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of pilavapadin and its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
What is Lexicon Pharmaceuticals (LXRX) presenting at the upcoming medical conferences?
When and where will LXRX present the pilavapadin clinical data?
What type of drug is pilavapadin and what condition does it treat?
Who will be presenting the pilavapadin data at these medical conferences?
